Citations

Clear

2391 citation(s) found for "Ma, Lin".

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes
Alsina, Melissa , Shah, Nina , Munshi, Nikhil C. , Jasielec, Jagoda, Timm, Alison, Turka, Ashley, Mao, Pingping, Martin, Nathan , Campbell, Timothy , Hege, Kristen , Raje, Noopur , Jagannath, Sundar , Madduri, Deepu , Kaufman, Jonathan L. , Siegel, David S. , Rosenblatt, Jacalyn , Lin, Yi , Jakubowiak, Andrzej , Bitter, Hans , Petrocca, Fabio , Berdeja, Jesús G.

Mayo Clinic

Blood | November 4, 2020 | Volume: 136 | Issue: Supplement 1 | Pages: 25-26

10.1182/blood-2020-140410 Get It

Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B-cell maturation antigen (BCMA) has shown promising results for the treatment of relapsed refractory multiple myeloma (RRMM). bb21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as idecabtagene vicleucel (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for memory-like T cells, thereby reducing the proportion of highly differentiated or senescent T cells. To investigate whether DP properties correlate with clinical outcomes including duration of response (DOR), we conducted extensive molecular characterization of patient DPs. Methods: CRB-402 (NCT03274219) is an ongoing, multi-center phase 1 dose escalation trial of bb21217 in RRMM patients who received ≥3 prior regimens, including proteasome inhibitor and immunomodulatory agent, or are double-refractory to both classes. In the expansion cohort, patients additionally required prior exposure to an anti-CD38 antibody and were required to be refractory to last line. Planned enrollment is 74 patients, including 50 in the expansion cohort. Patients undergo lymphodepletion with fludarabine (30 mg/m2) and cyclophosphamide (300 mg/m2) daily for 3 days, then receive a single infusion of bb21217 at 150, 300 or 450 x 106 CAR+ T cells. The primary outcome measure is incidence of adverse events (AEs), including dose-limiting toxicities (DLTs). Additional outcome measures include overall response rate and DOR by IMWG Uniform Response Criteria. We profiled DP and apheresis starting material (PBMC) by RNAseq and cyTOF and correlated expression of memory/senescence markers from apheresis to DP with clinical outcomes, including DOR. Results: Asof March 1, 2020, 46 patients (median age 62 [33-74]) received bb21217, 24 in escalation (12 at 150, 6 at 300 and 6 at 450) and 22 in expansion (8 at 300 and 14 at 450); median follow up for all patients is 8.5 (<1-29) months. Patients had a median of 6 (3-17) prior lines of therapy with 26/46 (57%) triple refractory. Cytokine release syndrome (CRS) developed in 31/46 (67%) patients and included one death (14 G1, 15 G2, 1 G3 and 1 G5). Median time to first onset was 3 days (1-20); tocilizumab (18 pts) +/- corticosteroids (6 pts) was used to manage CRS. Ten (22%) patients developed neurotoxicity [5 G1, 2 G2, 2 G3, 1 G4] with median time to first onset of 7 (3-24) days. Response was assessed per investigator for 44 patients with ≥ 2 months of follow up or PD/death within 2 months. Twenty-four (55%) patients had confirmed response per IMWG criteria including 8 (18%) with ≥CR and 13 (30%) with VGPR. Median time to CR was 2.5 (1-24) months. The median DOR was 11.9 (95% CI: 8.1-17.0) months across target dose levels of 150-450 x106 CAR+ T cells. The 450 target dose was selected as the RP2D and dose expansion is ongoing. bb21217 DPs from 44 patients were characterized. Paired analysis of T cells from PBMC and DP showed bb21217 DP is significantly enriched for memory-like T cells (LEF1+, CD27+, CCR7+) and depleted of highly differentiated or senescent CD57+ T cells. Patients with DPs most enriched for early memory markers (LEF1+, CCR7+ and CD27+) and with low expression of effector/exhaustion markers (EOMES+, GZMA+, CD57+) were more likely to have higher peak CAR+ T cell expansion. To evaluate the association of these DP markers with DOR, we split the 24 responders (≥PR) on median marker expression (high vs low) and analyzed DOR in these exploratory subgroups. High CD127 expression, associated with long-lasting memory T cell formation, was positively correlated with DOR, while multiple markers associated with differentiated T cells (e.g. EOMES+, TBET+) were negatively correlated with DOR. Conclusions: The adverse events observed are consistent with known toxicities of CAR T cell therapies. Initial efficacy results with bb21217 are encouraging, with 48% of patients treated across target dose levels of 150-450 obtaining ≥VGPR. The presence of T cell markers associated with memory and the absence of T cells markers associated with differentiation/senescence in DP correlated positively with peak expansion and DOR. These preliminary correlative data support the mechanistic hypothesis that enrichment for memory like T cells in bb21217 DP may result in improved clinical outcomes. Data for approximately 14 additional patients at the 450 target dose will be presented. Disclosures Alsina: Janssen: Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria; Amgen: Honoraria, Speakers Bureau; BMS: Consultancy, Research Funding. Shah:GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm: Consultancy; BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar: Research Funding. Raje:Janssen: Consultancy; Celgene: Consultancy; Immuneel: Membership on an entity's Board of Directors or advisory committees; Caribou: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy; Astrazeneca: Consultancy; Bluebird, Bio: Consultancy, Research Funding; Karyopharm: Consultancy; BMS: Consultancy; Amgen: Consultancy. Jagannath:Karyopharm: Consultancy, Honoraria; Legend Biotech: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Madduri:Janssen: Consultancy; BMS: Consultancy; Takeda: Consultancy; Legend: Consultancy; Sanofi: Consultancy; GSK: Consultancy; Kinevant: Consultancy; Foundation Medicine: Consultancy. Kaufman:Janssen: Consultancy, Honoraria; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Tecnopharma: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; AbbVie: Consultancy; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi/Genyzme: Consultancy, Honoraria. Siegel:Amgen: Consultancy, Honoraria, Speakers Bureau; Merck: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria, Speakers Bureau; Karyopharma: Consultancy, Honoraria; Celulatiry: Consultancy. Munshi:BMS: Consultancy; OncoPep: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; C4: Current equity holder in private company; Janssen: Consultancy; Adaptive: Consultancy; Legend: Consultancy; Amgen: Consultancy; AbbVie: Consultancy; Karyopharm: Consultancy; Takeda: Consultancy. Lin:Novartis: Consultancy; Celgene: Consultancy, Research Funding; Bluebird Bio: Consultancy, Research Funding; Juno: Consultancy; Legend BioTech: Consultancy; Merck: Research Funding; Takeda: Research Funding; Gamida Cells: Consultancy; Sorrento: Consultancy, Membership on an entity's Board of Directors or advisory committees; Vineti: Consultancy; Janssen: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding. Jakubowiak:AbbVie, Amgen, BMS/Celgene, GSK, Janssen, Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive, Juno: Consultancy, Honoraria. Timm:bluebird bio: Current Employment, Current equity holder in publicly-traded company. Turka:bluebird bio: Current Employment. Mao:bluebird bio: Current Employment, Current equity holder in publicly-traded company. Martin:BMS: Current Employment, Current equity holder in publicly-traded company. Campbell:BMS: Current Employment, Current equity holder in publicly-traded company. Hege:Arcus Biosciences: Divested equity in a private or publicly-traded company in the past 24 months; Mersana Therapeutics: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; BMS: Current Employment, Current equity holder in publicly-traded company, Other: Travel, accommodations, expenses, Patents & Royalties: Numerous, Research Funding. Bitter:Novartis AG, Predicant Biosciences, Biospect, F Hofmann-La Roche: Ended employment in the past 24 months; bluebird bio: Current Employment, Current equity holder in publicly-traded company; Novartis: Ended employment in the past 24 months, Patents & Royalties. Petrocca:bluebird, bio: Current Employment, Current equity holder in publicly-traded company. Berdeja:Celgene: Consultancy, Research Funding; Cellularity: Research Funding; Constellation: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; CURIS: Research Funding; EMD Sorono: Research Funding; Takeda: Consultancy, Research Funding; Servier: Consultancy; Teva: Research Funding; Prothena: Consultancy; Poseida: Research Funding; Novartis: Research Funding; Lilly: Research Funding; Legend: Consultancy; Kite Pharma: Consultancy; Kesios: Research Funding; Karyopharm: Consultancy; Janssen: Consultancy, Research Funding; Glenmark: Research Funding; Genentech, Inc.: Research Funding; BMS: Consultancy, Research Funding; Bioclinica: Consultancy; Bluebird: Research Funding; Acetylon: Research Funding; Amgen: Consultancy, Research Funding; Abbvie: Research Funding; Vivolux: Research Funding.
Assessment of Heterogeneity in Heart Failure–Related Meta-Analyses
Khan, Muhammad Shahzeb , Li, Lin , Yasmin, Farah , Pandey, Ambarish , Vaduganathan, Muthiah , Pandey, Ambarish , Khan, Safi U. , Bajaj, Navkaranbir Singh , Murad, M. Hassan , Fonarow, Gregg C. , Butler, Javed , Vaduganathan, Muthiah

Mayo Clinic

Circulation: Heart Failure | November 2, 2020 | Volume: 13 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.120.007070 | PMID 33131285 Get It

Background: Assessment of heterogeneity in meta-analyses is critical to ensure the consistency of pooled results. Therefore, we sought to assess the evaluation and reporting of heterogeneity in heart failure (HF) meta-analyses. Methods: Study level meta-analyses pertaining to HF were selected from January 2009 to July 2019, published in 11 high impact factor journals. We tabulated the overall proportion of the meta-analyses reporting statistical heterogeneity and specific metrics and methods employed to quantify and explore heterogeneity. Results: Of 126 HF meta-analyses (612 outcomes), heterogeneity was reported for 422 outcomes (68.9 %) in 108 meta-analyses. Out of the 422 outcomes reporting statistical heterogeneity, 137 outcomes (32.5%) had no observable heterogeneity: ( I 2 =0%), 40 outcomes (9.5%) had low heterogeneity ( I 2 <25%), 76 outcomes (18%) had moderate heterogeneity ( I 2 =25%–50%), and 169 outcomes (40%) had high heterogeneity ( I 2 >50%). Reporting of statistical heterogeneity was not significantly associated with year of publication, funding source, disclosure information, or the type of studies pooled. Sensitivity analysis (n=68) was the most common statistical technique employed to evaluate the source of heterogeneity followed by subgroup analyses (n=59) and meta-regression (n=40). Conclusions: Despite being an essential component of meta-analyses, heterogeneity was not reported for nearly 30% of outcomes and variably handled in contemporary HF meta-analyses. As meta-analyses increase across HF science, interpreting and handling of heterogeneity should be standardized.
Evaluation of Concordance Between Original Death Certifications and an Expert Panel Process in the Determination of Sudden Unexplained Death in Childhood
Gould, Laura , Lee, Joyce H. , Friedman, Daniel , Lear, Kelly, Maloney, Katherine F., Pinckard, J. Keith, Andrew, Thomas, Roman, Kristin, Landi, Kristen, Jarrell, Heather, Williamson, Alex , Downs, J. C. Upshaw, Pinneri, Kathy, William, Christopher , Maleszewski, Joseph J. , Reichard, R. Ross , Devinsky, Orrin , Lin, Peter , Devinsky, Orrin , Lin, Peter T. , Roman, Kristin

Mayo Clinic

JAMA Network Open | October 30, 2020 | Volume: 3 | Issue: 10 | Pages: e2023262

10.1001/jamanetworkopen.2020.23262 | PMID 33125496 Get It

S0495 The Safety Profile of Tegaserod 6 Mg BID in Irritable Bowel Syndrome With Constipation in Women
Lacy, Brian E. , Chey, William D. , Shah, Eric D. , Lacy, Brian E. , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S247-S247

10.14309/01.ajg.0000704028.06576.5a Get It

S0494 Efficacy of Tegaserod 6 mg BID for Treating Irritable Bowel Syndrome With Constipation in Women
Lacy, Brian E. , Chey, William D. , Shah, Eric D. , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S247-S247

10.14309/01.ajg.0000704024.89100.6d Get It

S0492 Tegaserod 6 Mg BID for Treating Abdominal Pain and Bloating in Women With Irritable Bowel Syndrome With Constipation but Without Cardiovascular Risk Factors: A Pooled Analysis of 4 Clinical Trials
Lacy, Brian E. , Chey, William D. , Shah, Eric D. , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S246-S246

10.14309/01.ajg.0000704016.06499.ec Get It

Contribution of Ictal Source Imaging for Localizing Seizure Onset Zone in Patients With Focal Epilepsy
Yang, Lin , Lu, Yunfeng , Brinkmann, Benjamin H. , Nelson, Cindy, He, Bin , Ye, Shuai, Kucewicz, Michał T. , Brinkmann, Benjamin, Sohrabpour, Abbas , He, Bin , Brinkmann, Benjamin H , Ye, Shuai , Nelson, Cindy, Worrell, Gregory A.

Mayo Clinic

Neurology | October 24, 2020 | Volume: 96 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000011109 | PMID 33097598 Get It

Using Artificial Intelligence to Measure Facial Expression following Facial Reanimation Surgery
Boonipat, Thanapoom , Lin, Jason , Glass, Graeme E. , Stotland, Mitchell A. , Stotland, Mitchell, Asaad, Malke , Mardini, Samir

Mayo Clinic

Plastic & Reconstructive Surgery | October 23, 2020 | Volume: 146 | Issue: 5 | Pages: 1147-1150

10.1097/prs.0000000000007251 | PMID 33136962 Get It

Summary: Social interactions are largely dependent on the interpretation of information conveyed through facial expressions. Although facial reanimation seeks restoration of the facial expression of emotion, outcome measures have not addressed this directly. This study evaluates the use of a machine learning technology to directly measure facial expression before and after facial reanimation surgery. Fifteen study subjects with facial palsy were evaluated both before and after undergoing cross-facial nerve grafting and free gracilis muscle transfer. Eight healthy volunteers were assessed for control comparison. Video footage of subjects with their face in repose and with a posed, closed-lip smile was obtained. The video data were then analyzed using the Noldus FaceReader software application to measure the relative proportions of seven cardinal facial expressions detected within each clip. The facial expression recognition application detected a far greater happy signal in postoperative (42 percent) versus preoperative (13 percent) smile videos (p < 0.0001), compared to 53 percent in videos of control faces smiling. This increase in postoperative happy signal was achieved in exchange for a reduction in the sad signal (15 percent to 9 percent; p = 0.092) and the neutral signal (57 percent to 37 percent; p = 0.0012). For video clips of patients in repose, no significant difference in happy emotion was detected between preoperative (3.1 percent) and postoperative (1.4 percent) states (p = 0.5). This study provides the first proof of concept for the use of a machine learning software application to objectively quantify facial expression before and after surgical reanimation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Diagnostic, IV.
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Rossi, John M. , Neelapu, Sattva S. , Jacobson, Caron A. , Miklos, David B. , Oluwole, Olalekan O. , Lekakis, Lazaros J. , Lin, Yi , Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen , Bot, Adrian , Oluwole, Olalekan O , Miklos, David B , Lin, Yi , Locke, Frederick L. , Ghobadi, Armin , Reagan, Patrick Michael

Mayo Clinic

Blood Advances | October 9, 2020 | Volume: 4 | Issue: 19 | Pages: 4898-4911

10.1182/bloodadvances.2020002394 | PMID 33035333 Get It

Abstract ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for secondary end point analysis were not clearly predictive of efficacy; these included Eastern Cooperative Oncology Group performance status (0 vs 1), age, disease subtype, disease stage, and International Prognostic Index score. We interrogated covariates included in the statistical analysis plan and an extensive panel of biomarkers according to an expanded translational biomarker plan. Univariable and multivariable analyses indicated that rapid CAR T-cell expansion commensurate with pretreatment tumor burden (influenced by product T-cell fitness), the number of CD8 and CCR7+CD45RA+ T cells infused, and host systemic inflammation, were the most significant determining factors for durable response. Key parameters differentially associated with clinical efficacy and toxicities, with both theoretical and practical implications for optimizing CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT02348216.
Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology
Hou, Xu , Cook, Casey , Liu, Chia‐Chen , Kang, Silvia S. , Lin, Wen‐Lang, DeTure, Michael , Diehl, Nancy N. , Al‐Shaikh, Fadi S. Hanna , Walton, Ronald L., Ross, Owen A. , Melrose, Heather L. , Ertekin‐Taner, Nilüfer , Bu, Guojun , Petrucelli, Leonard , Fryer, John Denis , Murray, Melissa E. , Fiesel, Fabienne C. , Springer, Wolfdieter , Watzlawik, Jens O. , Al-Shaikh, Fadi S Hanna, Liu, Chia-Chen , Ross, Owen A , Bu, Guojun , Fiesel, Fabienne C , Springer, Wolfdieter , Murray, Melissa E , Hou, Xu , Heckman, Michael G. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2020 | Volume: 17 | Issue: 3 | Pages: 417-430

10.1002/alz.12198 | PMID 33090691 Get It

Abstract Introduction The cytoprotective PTEN‐induced kinase 1 (PINK1)‐parkin RBR E3 ubiquitin protein ligase (PRKN) pathway selectively labels damaged mitochondria with phosphorylated ubiquitin (pS65‐Ub) for their autophagic removal (mitophagy). Because dysfunctions of mitochondria and degradation pathways are early features of Alzheimer's disease (AD), mitophagy impairments may contribute to the pathogenesis. Methods Morphology, levels, and distribution of the mitophagy tag pS65‐Ub were evaluated by biochemical analyses combined with tissue and single cell imaging in AD autopsy brain and in transgenic mouse models. Results Analyses revealed significant increases of pS65‐Ub levels in AD brain, which strongly correlated with granulovacuolar degeneration (GVD) and early phospho‐tau deposits, but were independent of amyloid beta pathology. Single cell analyses revealed predominant co‐localization of pS65‐Ub with mitochondria, GVD bodies, and/or lysosomes depending on the brain region analyzed. Discussion Our study highlights mitophagy alterations in AD that are associated with early tau pathology, and suggests that distinct mitochondrial, autophagic, and/or lysosomal failure may contribute to the selective vulnerability in disease.